KemPharm Inc (KMPH):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:KemPharm Inc (KMPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8045
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
KemPharm Inc (KemPharm) is a clinical-stage specialty pharmaceutical company that offers discovery and development of proprietary new molecular entity prodrugs. The company’s product pipeline includes KP415, methylphenidate drug for ADHD; KP201/IR, KP511/ER, KP606/IR and KP746 drugs for the treatment of pain. It also develops KP303 a quetiapine antipsychotic drug that treats multiple central nervous system disorders. KemPharm uses ligand activated therapy (LAT) a platform technology to produce new molecular entity prodrugs. The company offers its products in the therapeutic areas such as Attention deficit hyperactivity disorder (ADHD), pain, and other central nervous system indications. KemPharm is headquartered in Coralville, Iowa, the US.

KemPharm Inc (KMPH) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
KemPharm Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
KemPharm Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
KemPharm Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
KemPharm Enters into Licensing Agreement with Genco Sciences 11
KemPharm Enters into Licensing Agreement with Acura Pharma 12
Equity Offering 13
KemPharm Prices Public Offering of Shares for USD25 Million 13
KemPharm to Raise USD50 Million in Public Offering of Shares 15
KemPharm to Raise USD20 Million in Public Offering of Shares 16
KemPharm to Raise USD62.7 Million in Public Offering of Shares 17
KemPharm Raises USD56 Million in IPO 18
Debt Offering 20
KemPharm Raises USD86.3 Million in Private Placement of 5.5% Senior Notes Due 2021 20
KemPharm Raises USD10 Million in Private Placement of Notes 22
Asset Transactions 23
Shire Acquires Amphetamine Amino Acid Conjugate Products from KemPharm 23
KemPharm Inc – Key Competitors 24
KemPharm Inc – Key Employees 25
KemPharm Inc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Aug 09, 2018: KemPharm reports second quarter 2018 results 27
May 10, 2018: KemPharm Reports Q1 2018 Results 29
May 10, 2018: KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug; Reports Q1 2018 Results 31
Mar 29, 2018: KemPharm Reports Fourth Quarter and Year End 2017 Results 34
Nov 09, 2017: KemPharm Reports Third Quarter 2017 Results and Provides Corporate Update 36
Aug 10, 2017: KemPharm Reports Second Quarter 2017 Results 37
May 10, 2017: KemPharm Reports First Quarter 2017 Results 38
Mar 09, 2017: KemPharm Reports Fourth Quarter and Year End 2016 Results 39
Product News 40
11/16/2017: KemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA 40
11/06/2017: KemPharm Receives USAN Approval for “Asalhydromorphone” as Nonproprietary Name for Novel Prodrug Candidate, KP511 41
07/09/2018: KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD 42
06/09/2017: KemPharm to Present Clinical Data for KP511, an Opioid Prodrug Candidate, at the International Conference on Opioids 44
05/10/2018: KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug 45
03/20/2018: KemPharm Announces Positive Topline Results from KP415 Pharmacokinetic Study in Children and Adolescents With ADHD 46
Product Approvals 47
Sep 20, 2017: KemPharm Files IND for KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate 47
Clinical Trials 48
Sep 11, 2018: KemPharm announces positive topline results from oral human abuse potential trial of KP415 prodrug 48
Jan 08, 2018: KemPharm Initiates Pivotal Efficacy Trial of KP415 49
Aug 10, 2017: KemPharm Announces Preliminary Results from KP415 Pharmacokinetic Single and Multiple Dose Trial 50
Mar 16, 2017: KemPharm Presents Clinical Data for KP511 at American Academy of Pain Medicine’s Annual Meeting 51
Jan 09, 2017: KemPharm Reports Positive Data from Phase 1 Intranasal Pharmacokinetic Study of KP511, An Investigational Prodrug of Hydromorphone for the Treatment of Pain 52
Other Significant Developments 54
Oct 11, 2018: Kempharm provides highlights from KOL investor event focused on the ADHD treatment landscape 54
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
KemPharm Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
KemPharm Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
KemPharm Inc, Deals By Therapy Area, 2012 to YTD 2018 9
KemPharm Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
KemPharm Enters into Licensing Agreement with Genco Sciences 11
KemPharm Enters into Licensing Agreement with Acura Pharma 12
KemPharm Prices Public Offering of Shares for USD25 Million 13
KemPharm to Raise USD50 Million in Public Offering of Shares 15
KemPharm to Raise USD20 Million in Public Offering of Shares 16
KemPharm to Raise USD62.7 Million in Public Offering of Shares 17
KemPharm Raises USD56 Million in IPO 18
KemPharm Raises USD86.3 Million in Private Placement of 5.5% Senior Notes Due 2021 20
KemPharm Raises USD10 Million in Private Placement of Notes 22
Shire Acquires Amphetamine Amino Acid Conjugate Products from KemPharm 23
KemPharm Inc, Key Competitors 24
KemPharm Inc, Key Employees 25
KemPharm Inc, Other Locations 26

List of Figures
KemPharm Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
KemPharm Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[KemPharm Inc (KMPH):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bare Escentuals Inc.:企業の戦略的SWOT分析
    Bare Escentuals Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Moravske naftove doly AS:企業の戦略的SWOT分析
    Moravske naftove doly AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Julius Baer Group Ltd.:戦略・SWOT・企業財務分析
    Julius Baer Group Ltd. - Strategy, SWOT and Corporate Finance Report Summary Julius Baer Group Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Strongbridge Biopharma plc (SBBP):企業の財務・戦略的SWOT分析
    Summary Strongbridge Biopharma Plc (Strongbridge Biopharma), formerly Cortendo Plc is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases. The company’s marketed product KEVEYIS (dichlorphenamide) is indicated for the treatment of hypokalemic, hy …
  • PeptiDream Inc (4587)-製薬・医療分野:企業M&A・提携分析
    Summary PeptiDream Inc (PeptiDream) is a biopharmaceutical company that discovers and develops constrained peptides, small molecule, and peptide-drug conjugate therapeutics. The company develops peptide discovery platform system (PDPS), a peptide generation and selection platform. Its technologies i …
  • Denbury Resources Inc.:企業の戦略・SWOT・財務分析
    Denbury Resources Inc. - Strategy, SWOT and Corporate Finance Report Summary Denbury Resources Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Nigerian Breweries Plc:企業の戦略・SWOT・財務情報
    Nigerian Breweries Plc - Strategy, SWOT and Corporate Finance Report Summary Nigerian Breweries Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Luna Innovations Inc (LUNA):企業の製品パイプライン分析
    Summary Luna Innovations Inc (Luna) is an optical technology development company that research, develops and commercializes speed optics and fiber optic test products. The company provides products such as fiber optic sensing products, fiber optic test and measurement products, high speed optical pr …
  • T-System Inc:医療機器:M&Aディール及び事業提携情報
    Summary T-System Inc (T-System) is a provider of healthcare IT solutions with focus on emergency department documentation. T-System develops solutions for the episode-based care market, which includes emergency departments (EDs) in hospitals, freestanding emergency centers and urgent care centers. B …
  • Mizuho Trust & Banking Co Ltd:企業の戦略・SWOT・財務情報
    Mizuho Trust & Banking Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Mizuho Trust & Banking Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • OGK-2 (OGKB):企業の財務・戦略的SWOT分析
    OGK-2 (OGKB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Federal Grid Company of Unified Energy System (FEES):企業の財務・戦略的SWOT分析
    Federal Grid Company of Unified Energy System (FEES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s k …
  • A.P. Eagers Limited:戦略・SWOT・企業財務分析
    A.P. Eagers Limited - Strategy, SWOT and Corporate Finance Report Summary A.P. Eagers Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Fukuoka Financial Group Inc:企業の戦略・SWOT・財務情報
    Fukuoka Financial Group Inc - Strategy, SWOT and Corporate Finance Report Summary Fukuoka Financial Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Ameren Corporation (AEE)-エネルギー分野:企業M&A・提携分析
    Summary Ameren Corporation (Ameren) is a public utility holding company that generates, transmits and distributes electricity; and transmits and distributes natural gas through its subsidiaries. The company generates electricity through varied energy sources such as coal, nuclear, hydro, solar, natu …
  • Sunrun Inc (RUN):電力:M&Aディール及び事業提携情報
    Summary Sunrun Inc (Sunrun) is a residential solar, storage and energy services company. It designs, develops, installs, finances, insures, monitors and maintains the solar panels on homeowners’ roof. The company also offers services such as permitting, design approval, site inspection and utility i …
  • Orexo AB (ORX):企業の財務・戦略的SWOT分析
    Orexo AB (ORX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • CLAAS KGaA mbH:企業の戦略的SWOT分析
    CLAAS KGaA mbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Morinaga & Co., Ltd. (2201):企業の財務・戦略的SWOT分析
    Morinaga & Co., Ltd. (2201) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Red Electrica Corporacion SA (REE):電力:M&Aディール及び事業提携情報
    Summary Red Electrica Corporacion SA (REC), together with its subsidiaries undertakes electricity transmission and system operation and management of the transmission network for the Spanish electricity system. The company carries out the regulated activities through its principal subsidiary, Red El …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆